Liver cancer remains one of the most challenging global health problems due to their aggressive biological behavior and bad prognosis. Its growing incidence, as well as their high mortality rates, have been well documented in recent world studies, which underlines its great relevance in public health. Despite the advances in Medical Imaging and Treatment, the late diagnosis of this neoplasm continues to undermine the survival results.
Epidemiological investigations reveal that liver cancer occupies a prominent place among the main causes of cancer mortality worldwide, with marked regional differences in incidence and outcomes. There are substantial disparities between areas of high endemicity – often associated with hepatitis virus infections – and regions that record increases in cases due to changes in lifestyle factors. A recent report of the Lancet Commission warns that at least 60 % of these cases could be prevented.[1]
One of the biggest challenges in the management of liver cancer is the difficulty of early detection, as the disease usually remains asymptomatic to advanced stages. Conventional image modalities often do not detect small lesions, while serum biomarkers, used in isolation, offer limited sensitivity and specificity. In that context, recent studies advocate integrating image findings with molecular data to improve early diagnostic precision. In addition, the creation of multiplex tests that combine clinical, radiological and genetic parameters is emerging as a promising strategy. The identification and validation of new molecular biomarkers has become central to understand the pathogenesis of liver cancer and its clinical forecast.[2]
Surgical resection remains the only potentially curative treatment in hepatocellular carcinoma in an early phase and recent technological advances have significantly improved the precision of these interventions. Innovative procedures have been developed, such as the liver partition combined with vein ligure holder after thrombectomy to isolate the tumor and optimize the future hepatic remnant. Traditional treatment modalities, such as chemotherapy, radiotherapy and tumor embolization are increasingly complemented by new directed agents and immunotherapies. For example, immune control points inhibitors have emerged as promising agents capable of overcoming the limitations of conventional treatments in advanced hepatecellular carcinoma. However, the appearance of therapeutic resistances, particularly to first -line drugs such as Sorafenib, represents a great obstacle in the clinical management of liver cancer.[3]
Are you up to date with the debates in hepatecellular carcinoma – from the non -invasive diagnosis and advances in biomarkers to advanced locorregional and systemic treatments? Evaluate your knowledge with our clinical mini-examination.
